development revenue under collaborative agreements on Isis' condensed
consolidated statement of operations.
(2) Ibis' cost of commercial revenue has been classified as research and
development expenses on Isis' condensed consolidated statement of
Regulus Therapeutics LLC
Statements of Operations
Three Months Six Months
June 30, 2008 June 30, 2008
Research and development revenue under
collaborative agreements $656 $748
Total revenue 656 748
Research and development 1,606 2,918
General and administrative 917 1,132
Total operating expenses 2,523 4,050
Loss from operations $(1,867) $(3,302)
Regulus was formed in the third quarter of 2007; therefore it does not
have operating results for the first half of 2007.
Isis Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
June 30, December 31,
Cash, cash equivalents and short-term
investments $536,969 $193,719
Other current assets
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved